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Abstract
Despite the possible benefit from avoiding stone surgery with all its possible complications, oral chemolysis is rarely per-
formed in patients with urinary stones suspected of uric acid content. Among the reasons for its limited use is the sparse and 
low-quality data on its efficacy and the lack of reliable factors predicting its outcome. We thus performed a retrospective 
single-center cohort study of 216 patients (median patient age 63 years) with 272 renal (48%) and/or ureteral (52%) stones 
treated with oral chemolysis from 01/2010 to 12/2019. Patients with low urine pH (< 6), low stone density upon non-contrast 
enhanced computed tomography (NCCT), radiolucent urinary stones on plain radiography, and/or a history of uric acid 
urolithiasis were included. Potassium citrate and/or sodium/magnesium bicarbonate were used for alkalization (target urine 
pH 6.5–7.2). Median stone size was 9 mm, median stone density 430 Hounsfield Units. Patients with ureteral stones < 6 mm 
were excluded since stones this small are very likely to pass spontaneously. The stone-free status of each patient was evaluated 
after 3 months using NCCT. Oral chemolysis was effective with a complete and partial response rate of stones at 3 months 
of 61% and 14%, respectively; 25% of stones could not be dissolved. Lower stone density (OR = 0.997 [CI 0.994–0.999]; 
p = 0.008) and smaller stone size (OR = 0.959 [CI 0.924–0.995]; p = 0.025) significantly increased the success rate of oral 
chemolysis in multivariate logistic regression analysis. More precise stone diagnostics to exclude non-uric-acid stones could 
further improve outcome.
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Introduction
Urolithiasis is one of the most often diagnosed conditions 
in urology with a worldwide prevalence ranging from 5 to 
10% [1]. Treatment of urinary stones varies from case to 
case depending on multiple factors including size, location, 
stone composition, and patient symptoms [2, 3]. Treatment 
can be conservative, non-invasive (shock wave lithotripsy 
[SWL]), minimally invasive (drainage with double J-stent 
or nephrostomy tube, endourological techniques) or, rarely, 
invasive (open or robotic). Most stones are composed of 
calcium oxalate, but about 10% consist of uric acid leading 
to an estimated prevalence rate of uric acid stones of up 
to > 0.75% [4]. The presence of uric acid in stones is associ-
ated with low density upon non-contrast enhanced computed 
tomography (NCCT), radiolucency on conventional radiol-
ogy, and low urine pH [5]. Thus, historically conservative 
regimens that increase urine pH and thus can lead to dissolu-
tion of uric acid stones have been proposed for prevention 
and treatment of uric acid urolithiasis [6–9]. Nevertheless, 
and despite the possible benefit from avoiding stone surgery 
with all its possible complications, oral chemolysis is rarely 
performed—even if uric acid stone is highly suspected. 
Among the reasons for its limited use is the sparse and low-
quality data on its efficacy. The aim of the present study is 
to evaluate the effectiveness of oral chemolysis (alkalization 
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of urine) in the management of suspected uric acid stones 
and to identify possible factors that may improve patient 
selection.
Methods
Study population
A total of 332 patients with renal and/or ureteral stones 
received oral chemolysis between January 2010 and Decem-
ber 2019 at our institution to dissolve suspected uric acid 
stones with low urine pH (< 6) [10], radiolucency on plain 
radiography, low density on NCCT (< 450 Hounsfield units 
[HU]) [11], recurrent uric acid stones, and/or presence of 
uric acid crystals on urinalysis. Patients receiving urine 
alkalization with preventive intent following complete inter-
ventional stone removal or after spontaneous stone passage 
were excluded from our study. In addition, ureteral stones 
of small size (< 6 mm) were excluded to avoid the bias that 
their high rate of spontaneous stone passage might mislead-
ingly inflate the success rate of chemolysis [12]. As a result, 
data of 216 patients with a total of 272 stones were included 
in this study (Fig. 1).
Intervention‑urine alkalization
Oral chemolysis was performed using potassium citrate, 
sodium bicarbonate or magnesium bicarbonate. The selec-
tion of alkalization regimen was based on patient renal 
function, the tolerance of a given regimen, and whether they 
had a prior treatment of (recurrent) uric acid stones. Potas-
sium citrate was indicated as a starting treatment regimen for 
patients with good renal function (eGFR > 0.7 ml/kg/min). 
An initial dose of 20 mEq three times daily was prescribed 
and adapted according to follow-up urine pH measurements. 
In patients with acute renal function impairment, intoler-
able pain and/or pyelonephritis due to an obstructing stone, 
treatment was only initiated after drainage (double J-stenting 
or nephrostomy) and return of serum creatinine levels and 
blood infection parameters to normal. If potassium citrate 
was not tolerated, it was replaced by sodium bicarbonate to 
complete the course of treatment. Patients with chronic renal 
insufficiency were given sodium bicarbonate as the initial 
treatment regimen. Magnesium bicarbonate was only pre-
scribed for a single patient intolerant to both other regimens. 
For patients with hyperuricemia or a history of gout, xan-
thine oxidase inhibitor (allopurinol 100–300 mg/day) was 
added to the oral chemolysis regimen. Additionally, patients 
were advised to increase their fluid intake to at least 2.5 L/
day. Metabolic work-up, however, was only performed after 
the stone treatment.
Patient follow‑up
All patients had NCCT [5] and pH measurement (dipstick) as 
baseline diagnostics and were followed-up according to our 
institutional protocol. Patients were meticulously instructed 
about regular urine pH measurement (three times daily using 
dipstick test of a spot urine sample) and adapting the drug 
Fig. 1  – Study flow chart
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dosage accordingly. The targeted urine pH was 6.5–7.2 [13]. 
A first follow-up visit with discussion of the patient’s urine 
pH diary and urine pH measurement was performed after 
2 weeks. Patients receiving potassium citrate had an addi-
tional plasma potassium measurement. A second visit after 
another 2 weeks was requested of non-compliant patients 
only. Follow-up NCCT imaging was performed after the first 
6 weeks of oral chemolysis. If required (partial dissolution 
only), another 6 weeks of oral chemolysis was administered 
followed by another NCCT imaging if deemed necessary. 
In case of symptoms due to the stone, intolerance of the 
medications, lack of stone dissolution, or at the patient’s 
request, active stone removal was discussed with the patient 
at follow-up visits.
Outcome measures and statistical analysis
Statistical analyses were performed using SPSS v. 21.0 
(SPSS Inc., Chicago). Mean with standard deviation (SD) 
and median with range / interquartile range (IQR) were used 
to describe continuous and proportions of categorical varia-
bles, respectively. Stone size was defined as the largest diam-
eter of the three dimensions on axial and coronal images 
of the pre-treatment CT scan. Stone density was measured 
using bone windows on the magnified axial NCCT of the 
stone at maximal diameter. If there were multiple ipsilateral 
kidney stones, stone size was defined as the sum of the maxi-
mal length of the stones. Ureteral stones and contralateral 
renal stones were considered as distinct stones and counted 
separately. Complete response and thus stone-free status 
was defined as the absence of any visible stone fragments 
on follow-up NCCT scan. Primary outcome was the stone-
free status following urine alkalization therapy. Therefore, 
patients with no or partial response were analyzed together. 
When partial response was observed, the percentage of stone 
size reduction from initial stone size was calculated. Sec-
ondary outcome was to identify factors affecting the suc-
cess of oral chemolysis using a univariate and multivariate 
logistic regression model. Independent variables were age, 
gender, BMI, eGFR, initial urine pH, drugs increasing uric 
acid excretion, stone location in the urinary system, stone 
size, stone density, pre-chemoytic intervention, chemolytic 
regimen, and duration of chemolysis. Only variables with 
a p value ≤ 0.2 on univariate analyses were included in the 
multivariate model. A two-sided p value < 0.05 was consid-
ered statistically significant.
Results
The majority of patients were male (n = 162; 75.0%) with 
a median age of 63 years (Table 1). Median stone diam-
eter was 9 mm (IQR 7–15), median stone density was 430 
HU (IQR 380–500; Table 2). In more than half of patients 
(58.8%), a single course (6 weeks) of urine alkalization 
therapy was sufficient to reach the primary endpoint. In 11 
patients (5%), the urine alkalization medication had to be 
changed or stopped due to side effects. Overall, a response 
to oral chemolysis was observed in 75% (204/272) of stones: 
complete in 61.0% (166 of 272) and partial in 14% (38/272). 
Dissolution > 50% was documented in 30% (11/38) of stones 
with partial response. Additional stone intervention [SWL, 
flexible ureterorenoscopy (URS) percutaneous nephroli-
thotomy (PCNL)] was required in only 22.1% (60/272) of 
stones (Table 2). Stone composition analysis by infrared 
spectroscopy was available in 30 patients undergoing addi-
tional intervention and revealed that 40% of these patients 
had stones without uric acid content (Table 3).
While univariate analysis identified stone diameter 
(OR = 0.945; CI 0.915–0.977; p = 0.001), stone density 
(OR = 0.997; CI 0.995–0.999; p = 0.007), stone location 
in the ureter (OR = 2.564; CI 1.553–4.233; p < 0.001), and 
Table 1  Patient characteristics
IQR interquartile range, BMI body mass index, eGFR estimated glo-
merular filtration rate
Parameters Total number of 
patients−(216)
Gender, n (%)
 Male 162 (75.0)
 Female 54 (25.0)
Age (years), median (IQR) 63 (52—74)
BMI (kg/m2), median (IQR) 29.4 (25.9 – 33.8)
eGFR, median (IQR) 64.0 ( 48.0 – 81.0)
Gout, n (%)
 No 197 (91.2)
 Yes 19 (8.8)
Initial urine pH, n (%)
 5.0 159 (73.6)
 5.5 47 (21.8)
  ≥ 6.0 10 (4.7)
Alkalization specimen, n (%)
 Potassium citrate 202 (93.5)
 Sodium bicarbonate 22 (10.2)
 Magnesium bicarbonate 1 (0.5)
Duration of alkalization (weeks), n (%)
 6 127 (58.8)
 12 89 (40.2)
Treatment interruption (intolerance), n (%)
 No 11 (5.1)
 Yes 205 (94.9)
Xanthine oxidase inhibitors
 No 169 (78.2)
 Yes 47 (21.8)
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pre-chemolytic intervention (OR = 1.781; CI 1.063–2.982; 
p = 0.028) as statistically significant parameters, only stone 
density (OR = 0.997; CI = 0.994–0.999; p = 0.008) and stone 
size (OR = 0.959; CI 0.924–0.995; p = 0.025) remained sig-
nificantly associated with successful chemolysis in multi-
variate analysis (Table 4).
Discussion
We investigated the success rate of oral chemolysis in a 
large number of patients (n = 216) with renal and/or ureteral 
stones. The overall response rate (partial or total dissolu-
tion) was 75%; 61% of stones were completely, 14% partially 
dissolved after 3 months of oral chemolysis. Independent 
factors improving the outcome were lower stone density on 
NCCT and small stone size. Still, oral chemolysis was also 
effective in stones > 4 cm.
Uric acid stones rank as the second largest group of 
stones accounting for almost 10% of all urinary stones [4]. 
Up to 40% of all stones contain uric acid [5]. Active surgical 
treatments such as PCNL, URS and SWL are the mainstay 
modalities for patients with urinary stone disease regard-
less of stone composition. These techniques, however, are 
associated with a wide range of complications and contrain-
dications. Conservative oral chemolysis represents a non-
invasive alternative for treatment of stones with suspected 
uric acid content. In the present study, it had a high response 
rate of 75% and a low rate of 22.1% of secondary (active) 
stone intervention. Oral chemolysis was first described in 
1933 by Violle [14]. Between then and 1980 several treat-
ment regimens and dosing protocols were proposed [6, 7]. 
Thereafter—and following the advent of minimally inva-
sive stone therapy—only a few studies have examined this 
particular treatment option [15]. Up to the end of 2019 
most publications on this topic were of low quality and/or 
involved a limited number of patients. This paucity of data 
notwithstanding, both European and American guidelines 
recommend the use of urine alkalization regimens for treat-
ment and prevention of uric acid stones [2, 16].
The reported success rates of oral dissolution therapy at 
3 months range from 50 to 73% [17–21]. Some of the stud-
ies, however, included small-sized ureteral stones which 
might have passed spontaneously and thus account for a 
higher rate of “stone clearance” than our 61%. We there-
fore did not include ureteral stones < 6 mm in our study. 
Other studies had lower rates of complete dissolution. A 
prospective trial conducted by Elbaset et al. assessed the 
efficacy of oral dissolution therapy, SWL and a combina-
tion thereof [18]. For medium-sized renal stones from 1 to 
2.5 cm, the authors reported stone-free rates of 16% at one 
month of oral chemolysis and 50% at 3 months. A simi-
lar stone-free rate (53.2%) at three month follow-up was 
Table 2  Stone characteristics and treatment outcomes
a Total number of stones with partial response = 38
IQR interquartile range, HU Hounsfield units, NCCT non-contrast 
enhanced computed tomography, SWL shock wave lithotripsy, URS 
ureteroscopy, PCNL percutaneous nephrolithotomy
Stone and treatment parameters Total number of stones
n = 272
Stone diameter (mm), median (IQR) 9.0 (7.0 – 15.0)
Stone location (kidney), n (%) 131 (48.2)
 Renal pelvis 55 (20.2)
 Upper calyx 34 (12.5)
 Middle calyx 10 (3.7)
 Lower calyx 10 (3.7)
 Multiple locations 22 (8.1)
Stone Location (ureter), n (%) 141 (51.8)
 Proximal (including uretero-pelvic junc-
tion)
93 (34.2)
 Middle 21 (7.7)
 Distal 27 (9.9)
Side of the stone burden, n (%)
 Left 170 (62.5)
 Right 102 (37.5)
Intervention before alkalization, n (%)
 No intervention 89 (32.7)
 Double J 175 (64.3)
 Percutaneous nephrostomy 3 (1.1)
 SWL 3 (1.1)
 URS 1 (0.4)
 PCNL 1 (0.4)
Stone density upon NCCT (HU), median 
(IQR)
430 (360—500)
Alkalization outcome at 3 months, n (%)
 No response 68 (25.0)
 Partial response 38 (14.0)
 Complete response 166 (61.0)
Reduction of size in 38 stones with partial 
response (% reduction), median (IQR)a
36.6 (20.0–61.8)
Stone intervention following oral chemolysis
 No further treatment 212 (77.9)
 SWL 19 (7.0)
 URS 33 (12.1)
 PCNL 8 (2.9)
Table 3  Stone analyses of 30 
patients who required active 
stone treatment
Parameters
Uric acid proportion, n (%)
  < 10 12 (40.0%)
 10–49 2 (6.7%)
 50–90 3 (10.0%)
  > 90 13 (43.3%)
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reported by Elsawy et al. [20]. However, stones in their 
studies were larger compared to those in our study, sup-
porting our finding that stone size significantly influences 
stone dissolution at pre-defined time points after start of 
oral dissolution therapy. Thus when oral chemolysis was 
administered for 6 months the stone-free rate increased 
to 83% [18]. For large stones, therefore, oral chemoly-
sis should be prolonged to better achieve complete stone 
dissolution.
The main factors favoring the formation of uric acid 
stones are—besides genetic predisposition—acidic urine 
(pH < 6.0), hyperuricosuria, and low urine output [22]. 
Therefore, pharmacotherapy to increase the urine pH (urine 
alkalization) is recommended for successful dissolution of 
uric acid stones [5]. Currently, a urine pH of 6.5–7.2 is rec-
ommended for the treatment of uric acid stones [13, 23]. 
A further increase of urine pH should be avoided because 
it increases the risk of calcium phosphate stone formation 
[13, 24].
The efficacy of different alkaline solutions was examined 
in an in vitro experimental study by Heimbach et al. [25]. 
Potassium citrate is the most often used regimen for oral dis-
solution therapy. Its wide acceptance is based on evidence 
that potassium urate is more soluble in the urine than sodium 
urates [22]. While most of its side effects are of a mild gas-
trointestinal character (flatulence, abdominal pain, nausea, 
vomiting, diarrhea) and can be avoided with the simultane-
ous intake of sufficient liquid or with meals/snacks, a poten-
tially dangerous side effect is hyperkalemia [4, 17]. Potas-
sium citrate, therefore, should be avoided in patients with 
advanced renal insufficiency [24]. Sodium bicarbonate and 
sodium citrate represent alternative regimens [6].
Importantly, only 11 of our patients had to discontinue 
treatment due to intolerable side effects. Strict routine 
Table 4  Factors affecting 
chemolysis outcome on 
univariate and multivariate 
analyses
Bold indicates the result of statistical significance
OR odds ratio, CI confidence interval, HU Hounsfield units, Ref reference
Variables Univariate Multivariate
OR (95% CI) p value OR (95% CI) p value
Age 0.986 (0.969–1.004) 0.117 0.981 (0.961–1.001) 0.064
Gender
 Male Ref
 Female 1.313 (0.748–2.304) 0.342
Gout
 No Ref
 Yes 1.303 (0.508 – 3.341) 0.582
BMI 1.001 (0.963–1.04) 0.966
Drugs increasing uric acid excretion
 No Ref
 Yes 1.402 (0.751–2.62) 0.289
Initial urine pH
  < 5.5 Ref
  ≥ 5.5 0.962 (0.541–1.712) 0.895
Stone diameter 0.945 (0.915–0.977) 0.001 0.959 (0.924–0.995) 0.025
Stone location
 Kidney Ref
 Ureter 2.564 (1.553–4.233) < 0.001 1.866 (0.984–3.539) 0.056
Stone HU 0.997 (0.995–0.999) 0.007 0.997 (0.994–0.999) 0.008
Pre-chemolytic intervention
No Ref
Yes 1.781 (1.063–2.982 0.028 1.222 (0.639–2.337) 0.544
Chemolytic regimen
 Potassium citrate Ref
 Sodium citrate 0.861 (0.532–1.391) 0.54
Treatment courses
(6 weeks)
 1 Ref
 2 0.827 (0.506–1.352) 0.45
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follow-up and wise consultation allowed us to monitor 
patients and detect those with hyperkalemia, to minimize 
side effects and ensure patients’ compliance with taking the 
prescribed medication.The knowledge of stone composition 
at diagnosis can greatly improve the effectiveness of oral 
chemolysis as it would exclude stones mistakenly thought 
to be of uric acid content. Novel technologies such as dual-
energy CT can more accurately distinguish between uric 
acid and non-uric acid stones than conventional CT [26]. 
Because we used only conventional NCCT in our study, a 
high percentage of non-uric acid stone content (mainly cal-
cium phosphate content) was present in 14 of 30 patients 
with available stone analysis and who had to undergo active 
stone removal. Since eight of these patients had a partial 
response to oral chemolysis (the other six had no response 
at all) before active treatment, we hypothesize that they 
had mixed-content stones and the observed partial dissolu-
tion was due to uric acid admixture. The other 16 patients 
with stone analysis after active stone removal had uric acid 
stone composition > 50%. More detailed analysis of these 16 
patients showed that they were either partially non-compli-
ant (n = 11) or developed side effects or intolerance that led 
them to stop the medication (n = 5). As a consequence, the 
urine of these 16 patients did not reach the target pH value 
of > 6.5 and oral dissolution therapy failed.
It has been shown that metabolic syndrome and obesity 
predispose to urinary stone formation. Particularly, uric 
acid stones are more prevalent in obese patients [1, 27]. Our 
cohort of patients had a high median BMI of 29.4 kg/m2 
and 36 were even morbidly obese (BMI > 35.0 kg/m2). We 
found, however, no association between BMI and the suc-
cess rate of oral chemolysis, an indication that oral chemoly-
sis is also effective in obese patients. In contrast, for active 
treatment modalities such as SWL, URS and PCNL, higher 
BMI decreases stone-free rates and increases the incidence 
of postoperative complications [28, 29]. In light of this, oral 
dissolution therapy might be of special interest for this sub-
group of patients.
To our knowledge, this study presents the largest cohort 
of patients with presumed uric acid stones treated with oral 
chemolysis alone and followed with NCCT imaging. Our 
study, however, has several limitations. The main limitation 
is its retrospective nature. Although our institution imple-
ments strict follow-up protocols to limit errors, potential bias 
cannot be fully eliminated. Another limitation is that ure-
teral stones that might have passed spontaneously were also 
included and might have positively influenced outcome. To 
minimize this potential bias, however, we excluded patients 
with small ureteral stones (< 6 mm). As a consequence, 
ureteral stone localization did not independently influence 
stone-free rate in multivariate analysis.
Another criticism might be that a high percentage of 
patients (64.3%) had undergone previous ureteral stenting 
(due to obstruction of the upper urinary tract) which is 
reported to significantly increase the success rate of oral che-
molysis [30]. However, multivariate analysis did not reveal 
any influence of previous stenting on the stone-free rate.
Conclusions
Oral chemolysis with urine alkalization is an effective 
and safe treatment modality for patients with ureter and 
kidney stones of suspected uric acid composition; com-
plete response at 3 months was achieved in 61.0% of these 
stones. Lower stone density on CT and smaller stone size 
significantly improved the outcome of oral chemolysis. Most 
patients were spared active interventional stone therapy with 
all its potential complications; additional active stone treat-
ment was only required in 22.1% of stones after unsuccessful 
complete oral chemolysis. More accurate stone composition 
diagnostics to exclude non-uric acid containing stones could 
further improve outcomes.
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